Solvonis to buy Awakn Life Sciences for around GBP5 million

(Alliance News) - Solvonis Therapeutics PLC on Monday said it entered into an arrangement ...

Alliance News 24 February, 2025 | 12:23PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Solvonis Therapeutics PLC on Monday said it entered into an arrangement agreement to buy Toronto-based Awakn Life Sciences Corp.

Solvonis is a London-based biotechnology company aiming to develop innovative treatments for mental health and substance use disorders, while Awakn Life is a biotechnology company that develops therapeutics for substance use disorders and addiction.

Solvonis expects the acquisition to complete in the second quarter of 2025.

Solvonis intends to issue about 2.07 billion new shares for the proposed acquisition as consideration for the takeover, valuing Awakn at around GBP5.0 million.

Separately, Solvonis said pretax loss narrowed to GBP1.1 million in the nine months to September 30, from GBP1.5 million a year prior. It reported no revenue, down from GBP380,000.

Administrative costs reduced to GBP1.1 million from GBP1.2 million.

Further, Solvonis reported a GBP139,000 gain on deconsolidation, compared to no such gain a year ago.

Solvonis shares were 1.2% lower at 0.17 pence each on Monday afternoon in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Solvonis Therapeutics PLC Ordinary Share 0.17 GBX -2.86 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures